MC-1 (pyridoxal 5′-phosphate): Novel therapeutic applications to reduce ischaemic injury

Expert Opinion on Investigational Drugs

Volumn 14, Issue 11, 2005, Pages 1435-1442

  Kandzari, David E ^a   Dery, Jean Pierre ^a   Armstrong, Paul W ^b   Douglas, Deborah A ^c   Zettler, Marjorie E ^c   Hidinger, G Karl Gunnar ^c   Friesen, Albert D ^c   Harrington, Robert A ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c Medicure International Inc   (Canada)

Author keywords

Coronary revascularisation; Ischaemia reperfusion injury; P2 purinergic receptors; Pyridoxal 5 phosphate; Stroke

Indexed keywords

ADENOSINE TRIPHOSPHATE; CREATINE KINASE MB; MC 1; PLACEBO; PURINE P2 RECEPTOR; PURINE RECEPTOR; PYRIDOXAL 5 PHOSPHATE;

ACUTE DISEASE; ARTICLE; ATHEROSCLEROSIS; BLEEDING DISORDER; BONE PAIN; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY RECANALIZATION; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ELECTIVE SURGERY; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; ISCHEMIA; METABOLIC DISORDER; MICROVASCULARIZATION; MORBIDITY; MORTALITY; MYALGIA; NEUROPROTECTION; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; REPERFUSION INJURY; STATISTICAL SIGNIFICANCE; STROKE; THROMBOSIS;

ANIMALS; CLINICAL TRIALS; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; PYRIDOXAL PHOSPHATE;

EID: 27744550634     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.11.1435     Document Type: Article

References (53)

1. BRAUNWALD E, KLONER RA: Myocardial reperfusion: a double-edged sword? J. Clin. Invest. (1985) 76:1713-1719.
2. KLONER RA: Does reperfusion injury exist in humans? J. Am. Coll. Cardiol. (1993) 21:537-545.
3. ROE MT, OHMAN EM, MAAS AC et al.: Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion. J. Am. Coll. Cardiol. (2001) 37:9-18.
4. AMERICAN HEART ASSOCIATION: Heart disease and stroke statistics - 2005 update. Dallas, USA (2005).
5. LOPEZ AD, MURRAY CC: The global burden of disease, 1990-2020. Nat. Med. (1998) 4:1241-1243.
6. WANG X, DAKSHINAMURTI K, MUSAT S, DHALLA NS: Pyridoxal-5′-phosphate is an ATP receptor antagonist in freshly isolated cardiomyocytes. J. Mol. Cell. Cardiol. (1999) 31:1063-1072.
7. KANDZARI DE, LABINAZ M, CANTOR WJ et al.: Reduction of myocardial ischemic injury following coronary intervention (the MC-1 to eliminate necrosis and damage trial). Am. J. Cardiol. (2003) 92:660-664.
8. FONDA ML, TRAUSS C, GUEMPEL UM: The binding of pyridoxal 5′-phosphate to human serum albumin. Arch. Biochem. Biophys. (1991) 288:79-86.
9. BODE W, VANDENBERG H: Pyridoxal-5′-phosphate and pyridoxal biokinetics in male wistar rats fed graded levels of vitamin B-6. J. Nutr. (1991) 121:1738-1745.
10. MIDDLETON HM: Intestinal absorption of pyridoxal-5′-phosphate: disappearance from perfused segments of rat jejunum in vivo. J. Nutr. (1979) 109:975-981.
11. MIDDLETON HM: Intestinal hydrolysis of pyridoxal 5′-phosphate in vitro and in vivo in the rat. Effect of protein binding and pH. Gastroenterology (1986) 91:342-350.
12. MEHANSHO H, HAMM MW, HENDERSON LM: Transport and metabolism of pyridoxal and pyridoxal phosphate in the small intestine of the rat. J. Nutr. (1979) 109:1542-1551.
13. TURNER JM: Pyridoxal phosphate breakdown by an alkaline phosphatase preparation. Biochem. J. (1961) 80:663-668.
14. MORISUE T, MORINO Y, SAKAMOTO Y, ICHIHARA K: Enzymatic studies on pyridoxine metabolism III. Pyridoxine phosphate oxidase. J. Biochem. (1960) 48:28-36.
15. ELIOT AC, KIRSCH JF: Pyridoxal phosphate enzymes: mechanistic, structural, and evolutionary considerations. Ann. Rev. Biochem. (2004) 73:383-415.
16. VENEGAS A, MARTIAL J, VALENZUELA P: Active site-directed inhibition of E. coli DNA-dependent RNA polymerase by pyridoxal 5′-phosphate. Biochem. Biophys. Res. Commun. (1973) 55:1053-1059.
17. MARTIAL J, ZALDIVAR J, BULL P, VENEGAS A, VALENZULA P: Inactivation of rat liver RNA polymerascs I and II and yeast RNA polymerase I by pyridoxal 5′-phosphate: evidence for the participation of lysyl residues at the active site. Biochemistry (1975) 14:4907-4911.
18. BASU A, TIRUMALAI RS, MODAK MJ: Substrate binding in human immunodeficiency virus reverse transcriptase. An analysis of pyridoxal 5′-phosphate sensitivity and identification of lysine 263 in the substrate-binding domain. J. Biol. Chem. (1989) 264:8746-8752.
19. MODAK MJ: Observations on the pyridoxal 5′-phosphate inhibition of DNA polymerases. Biochemistry (1976) 15:3620-3626.
20. DIFFLEY JF: Affinity labeling the DNA polymerase α complex: pyridoxal 5′-phosphate inhibition of DNA polymerase and DNA primase activities of the DNA polymerase-α complex from Drosophila melanogaster embryos. J. Biol. Chem. (1988) 263:14669-14677.
21. KATUNUMA N, MATSUI A, INUBUSHI T et al.: Structure-based development of pyridoxal propionate derivatives as specific inhibitors of cathespin K in vitro and in vivo. Biochem. Biophys. Res. Commun. (2000) 267:850-854.
22. YAMASHIMA T, ZHAO L, WANG XD, TSUKADA T, TONCHEV AB: Neuroprotective effects of pyridoxal phosphate and pyridoxal against ischemia in monkeys. Nutr. Neurosci. (2001) 4:389-397.
23. MILAVETZ JJ, GIEBEL DW, CHRISTIAN TF, SCHWARTZ RS, HOLMES DR, GIBBONS RJ: Time to therapy and salvage in myocardial infarction. J. Am. Coll. Cardiol. (1998) 31:1246-1251.
24. DE LUCA G, SURYAPRANATA H, ZIJLSTRA F et al.: ZWOLLE MYOCARDIAL INFARCTION STUDY GROUP. Symptom-onset-to-balloon time and mortality in patients with acute myocardial infarction treated by primary angioplasty. J. Am. Coll. Cardiol. (2003) 42:991-997.
25. LANGLOIS PF, GAWRYL MS: Detection of the terminal complement complex in patient plasma following acute myocardial infarction. Atherosclerosis (1988) 70:95-105.
26. SHERIDAN FM, COLE PG, RAMAGE D: Leukocyte adhesion to the coronary microvasculature during ischemia and reperfusion in an in vivo canine model. Circulation (1996) 93:1784-1787.
27. REIMER KA, LOWE JE, RASMUSSEN MM, JENNINGS RB: The wavefront phenomenon of ischemic cell death: myocardial infarct size versus duration of coronary occlusion in dogs. Circulation (1977) 56:786-794.
28. BOLLI R: Mechanism of myocardial 'stunning'. Circulation (1990) 82:723-738.
29. CLEMENS MG, FORRESTER T: Appearance of adenosine triphosphate in the coronary sinus effluent from isolated working rat heart in response to hypoxia. J. Physiol. (1981) 312:143-158.
30. FORRESTER T, WILLIAMS CA: Release of adenosine triphosphate from isolated adult heart cells in response to hypoxia. J. Physiol. (1977) 268:371-390.
31. INGERMAN CM, SMITH JB, SILVER MJ: Direct measurement of platelet secretion in whole blood. Thromb. Res. (1979) 16:335-344.
32. 1-adrenoceptor stimulation. Br. J. Pharmacol. (1994) 113:1203-1208.
33. YANG S, CHEEK DJ, WESTFALL DP, BUXTON IL: Purinergic axis in cardiac blood vessels. Agonist-mediated release of ATP from cardiac endothelial cells. Circ. Res. (1994) 74:401-407.
34. VASSORT G: Adenosine 5′-triphosphate: a P2-purinergic agonist in the myocardium. Physiol. Rev. (2001) 81:767-807.
35. TREZISE DJ, BELL NJ, KHAKH BS, MICHEL AD, HUMPHREY PA: P2 purinoreceptor antagonist properties of pyridoxal-5-phosphate. Eur. J. Pharmacol. (1994) 259:295-300.
36. DUBYAK GR, EL MOATASSIM C: Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides. Am. J. Physiol. (1993) 265:C577-C606.
37. HARDEN TK, BOYER JL, NICHOLAS RA: P2-purinergic receptors: subtype associated signaling response and structure. Ann. Rev. Pharmacol. Toxicol. (1994) 35:541-579.
38. HOURANI SM, HALL DA: P2T purinoceptors: ADP receptors on platelets. Ciba Found. Symp. (1996) 198:53-64.
39. DUBYAK GR, COWEN DS, LAZARUS HM: Activation of inositol phospholipid signaling system by receptors for extracellular ATP in human neutrophils, monocytes, and neutrophil/monocyte progenitor cells. Ann. NY. Acad. Sci. (1988) 551:218-237.
40. 2 integrin) surface expression on peripheral blood leucocytes. Biochem. Biophys. Res. Commun. (1997) 233:71-75.
41. VENTURA MA, THOMOPOULOS P: ADP and ATP activate distinct signaling pathways in human promonocytic U-937 cells differentiated with 1,25-dihydroxy-vitamin D3. Mol. Pharmacol. (1995) 47:104-114.
42. VULCHANOVA L, ARVIDSSON U, RIEDL M et al.: Differential distribution of two ATP-gated channels (P2X receptors) determined by immunocytochemistry. Proc. Natl. Acad. Sci. USA (1996) 93:8063-8067.
43. BURNSTOCK G: Vascular control by purines with emphasis on the coronary system. Eur. Heart J. (1989) 10(Suppl. F):15-21.
44. WANG CX, YANG T, NOOR R, SHUAIB A: Role of MC-1 alone and in combination with tissue plasminogen activator in focal ischemic brain injury in racs. J. Neurosurg. (2005) 103:165-169.
45. KONG TQ, DAVIDSON CJ, MEYERS SN, TAUKE JT, PARKER MA, BONOW RO: Prognostic implication of creatine kinase elevation following elective coronary artery interventions. JAMA (1997) 277:461-466.
46. TARDIFF BE, CALIFF RM, TCHENG JE et al.: Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. J. Am. Coll. Cardiol. (1999) 33:88-96.
47. HARRINGTON RA, LINCOFF AM, CALIFF RM et al.: Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT). J. Am. Coll. Cardiol. (1995) 25:1693-1699.
48. SAUCEDO JF, MEHRAN R, DANGAS G et al.: Long-term clinical events following creatine-myocardial band isoenzyme elevation after successful coronary stenting. J. Am. Coll. Cardiol. (2000) 35:1134-1141.
49. GRANDE P, CHRISTIANSEN C, PEDERSEN A: Influence of acute myocardial infarct size on acute and one-year mortality. Eur. Heart J. (1983) 4:20-25.
50. LAMAS GA, FLAKER GC, MITCHELL G et al.: FOR THE SURVIVAL AND VENTRICULAR ENLARGEMENT INVESTIGATORS: Effect of infarct artery patency on prognosis after acute myocardial infarction. Circulation (1995) 92:1101-1109.
51. MAYNARD C, WEAVER WD, LITWIN PE et al.: FOR THE MITI PROJECT INVESTIGATORS: Hospital mortality in acute myocardial infarction in the era of reperfusion therapy (The Myocardial Infarction Triage and Intervention Project). Am. J. Cardiol. (1993) 72:877-882.
52. DI VIRGILIO F, CHIOZZI P, FALZONI S et al.: Cytolytic P2X purinoceptors. Cell Death Differ. (1998) 5:191-199.
53. FRISO S, JACQUES PF, WILSON PW et al.: Low circulating vitamin B6 is associated with elevation of the inflammatory marker C-reactive protein independently of homocysteine levels. Circulation (2001) 103:2788-2791.